Investor Alert

Market Pulse Archives

July 30, 2021, 8:39 a.m. EDT · CORRECTED

AbbVie cites growth of immunology business in the second quarter

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    AbbVie Inc. (ABBV)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

An earlier version of this report incorrectly cited AbbVie's updated EPS guidance for 2021. It has been corrected.

AbbVie Inc. /zigman2/quotes/202428675/composite ABBV +0.55% beat expectations for the second quarter of 2021, driven largely by gains in its immunology business. The drug maker had earnings of $766 million, or 42 cents per share, in the second quarter of 2021. It had a loss of $738 million, or 46 cents per share, in the same quarter a year ago. Adjusted earnings per share were $3.11, against a FactSet consensus of $3.08. AbbVie said its revenue jumped to $13.9 billion for the quarter, up from $10.4 billion in the same period a year ago. The FactSet consensus was $13.6 billion. The company said sales of several marquee drugs increased in the second quarter, including arthritis therapy Humira to $5.0 billion and Botox Cosmetic, which the drug maker gained as part of its acquisition of Allergan, to $584 million. The company updated its guidance for the year, saying it now expects EPS of $6.04 to $6.14, compared with past guidance of $7.27 to $7.47. It also updated guidance for adjusted EPS and now expects a range of $12.52 to $12.62, compared with previous guidance of $12.37 to $12.57. AbbVie's stock is up 10.4% so far this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -1.18% is up 17.6%.

$ 115.91
+0.63 +0.55%
Volume: 6.29M
Dec. 1, 2021 4:02p
P/E Ratio
Dividend Yield
Market Cap
$203.80 billion
Rev. per Employee
-53.96 -1.18%
Volume: 3.04B
Dec. 1, 2021 5:04p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.